Date: 2015-10-01
Type of information: Collaboration agreement
Compound:
Company: Biogen (USA - MA) Genomics (UK)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism:
Disease:
Details: * On October 1, 2015, Genomics, a leading analysis company developing algorithms, data resources, and software solutions to uncover the relationships between genetic variation and human disease, announced that it has entered into a collaboration agreement with Biogen. The collaboration aims to refine drug target selection through the use of sophisticated analysis of human genetic data. Under the terms of the agreement Biogen will leverage findings from Genomics’ integrated database and state-of-the-art analysis tools, which will be used to guide drug research and development. Biogen will use these findings to help answer questions regarding the likely efficacy and safety of their intended drug targets.
Genomics has developed a unique analytical platform for genomic data analysis and interpretation. The platform combines proprietary algorithms and software with the Company’s integrated genome-phenome database and analytical expertise to uncover the relationships between genetic variation and human health outcomes. Genomics has several existing partnerships with large pharmaceutical companies, and in clinical genomics is a platform partner for Genomics England, the company undertaking the 100,000 Genomes project in the UK.
Financial terms:
Latest news:
